The annual meeting of the American Academy of Otolaryngology-Head and Neck Surgery was held from Sept. 15 to 18 in New Orleans and attracted more than 7,000 participants from around the world, including otolaryngologists, medical experts, allied health professionals, and administrators. Presentations focused on the latest advances in the diagnosis and treatment of disorders of the ears, nose, throat, and related structures of the head and neck.
In one study, Alana N. Aylward, M.D., of the University of Utah in Salt Lake City, and colleagues evaluated the use of steroids in children with known hearing loss with progression. The investigators used a novel method of intratympanic steroid administration by placing tympanostomy tubes followed by administration of dexamethasone drops daily at home.
“Fluctuating progressive hearing loss is difficult to evaluate; however, hearing appeared to stabilize or improve with steroid administration, whether intratympanic, systemic, or both,” Aylward said. “Children with enlarged vestibular aqueduct, trauma, or idiopathic loss appeared to do better with steroids.”
The investigators also found that a few children did have side effects from intratympanic steroid administration.
“Children with worsening hearing loss may benefit from steroids, either systemic and/or intratympanic, particularly those with hearing loss due to enlarged vestibular aqueduct, trauma, or idiopathic loss,” Aylward said.
In another study, Kevin J. Contrera, M.D., M.P.H., of the Cleveland Clinic, and colleagues examined patterns of recurrence and progression for paragangliomas of the head and neck based on one of the largest samples of this patient population to date. The investigators presented the first evidence-based recommendations on long-term management of patients following treatment for head and neck paraganglioma.
“In patients treated for head and neck paragangliomas, recurrence is gradual and metastasis is rare. Recurrence is more common with glomus jugulare tumors and less common with carotid body tumors,” Contrera said. “Radiation may offer a lower risk of recurrence or progression than surgery for some paraganglioma types. Metastasis is rare but more likely with recurrent disease. Long-term follow-up is necessary to identify recurrences which frequently occur decades after treatment.”
The European Society of Endocrinology, according to Contrera, had previously put forth guidelines recommending repeat imaging every one to two years after treatment.